JOURNAL NOUVELLES CHOMEDEY NEWBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL NOUVELLES CHOMEDEY NEW
Company Title:
Company Description:
Keywords to Search:
Company Address:	657 Boul Cure-Labelle #250,LAVAL,QC,Canada
ZIP Code: Postal Code:	H7V2T8
Telephone Number:	4509789999
Fax Number:	4506876330
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	5 to 9
Sales Amount:	$1 to 2.5 million
Credit History: Credit Report:	Excellent
Contact Person:	George Bakoganis
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JOYAUX DE REVES
JOYAL & BOLDUC BURLOC
JOVIN

Next company profile:
JOURNAL LENQUETEUR
JOURNAL IMPACT CAMPUS
JOURNAL INDUSTRIEL DU QUEBEC

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease . . .
Targeted DNA Methylation Using Modified DNA Probes: A Potential Therapeutic Tool for Depression and Stress-Related Disorders, International Journal of Molecular Sciences, 26, 12, (5643), (2025
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Uncontrolled hypertension remains a leading cause of cardiovascular complications and death from cardiovascular disease 1 Despite the use of multidrug regimens, reaching recommended blood
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
A total of 1721 patients (1680 adults and 41 adolescents) underwent randomization and received brensocatib or placebo The annualized rate of pulmonary exacerbations was 1 02 in the 10-mg
Recently Published - The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)